For CRC, the mutational status of the genes KRAS and BRAF receives additional attention as they can negatively affect the patient’s response towards anti-EGFR therapies, with the prevalence of somatic KRAS mutations being 40% [109]. This evidence concerns the gene BRAF and colorectal carcinoma.